Eiger BioPharmaceuticals Inc

NASDAQ:EIGR   11:51:56 AM EDT
8.40
+0.06 (+0.72%)
Earnings Announcements

Eiger Announces Results Of Investigator Sponsored Study In Outpatients With Mild And Uncomplicated Covid-19

Published: 09/28/2020 12:23 GMT
Eiger BioPharmaceuticals Inc (EIGR) - Eiger Announces Results of Investigator Sponsored Study in Outpatients With Mild and Uncomplicated Covid-19.
Eiger Biopharmaceuticals - No Difference Was Demonstrated in Duration of Sars-cov-2 Viral Shedding and Time to Symptom Resolution Versus Placebo.
Eiger Biopharmaceuticals Inc - Lambda Was Well-tolerated With Few Adverse Events, Which Included Elevated Transaminases Which Self-resolved.
Revenue is expected to be $2.11 Million
Adjusted EPS is expected to be -$0.49

Next Quarter Revenue Guidance is expected to be $3.17 Million
Next Quarter EPS Guidance is expected to be -$0.45

More details on our Analysts Page.